Combination therapy with decitabine and olaparib in poly(ADP-ribose) polymerase inhibitor (PARPi) resistant high grade serous ovarian cancer

被引：0
作者：
Shafa, A. [1 ]
Hou, X. [2 ]
Wang, L. [3 ]
Weroha, S. J. [2 ]
机构：
[1] Mayo Clin, Gynecol Oncol, Rochester, MN USA
[2] Mayo Clin, Oncol, Rochester, MN USA
[3] Mayo Clin, Mol Pharmacol & Expt Therapeut, Rochester, MN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151
引用
收藏
页码：S54 / S54
页数：1
相关论文
共 50 条
  • [1] Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy
    Miller, Rowan E.
    CANCER JOURNAL, 2021, 27 (06) : 506 - 510
  • [2] Combination therapy with poly (ADP-ribose) polymerase inhibitor in endometrial cancer
    Xu, Conway
    Hou, Xiaonan
    Jessen, Erik
    Wang, Chen
    Weroha, S. John
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer
    Parkes, Eileen E.
    Kennedy, Richard D.
    ONCOLOGIST, 2016, 21 (05) : 586 - 593
  • [4] Use of DNA methyltransferase inhibitor and poly(adenosine diphosphate ribose) polymerase inhibitor (PARPi) in the treatment of PARPi-resistant, high-grade serous ovarian cancer
    Shafa, Anousheh
    Hou, Xiaonan
    Wang, Liewei
    Weroha, S. John
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S229 - S229
  • [5] A guide to poly ADP-ribose polymerase inhibitor (PARPi) toxicity management
    Patel, Shrina Divyesh
    Joseph, Donyika Ann
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (07) : 916 - 916
  • [6] Poly (ADP-Ribose) polymerase inhibitors (PARPI): Associated thrombosis in patients with ovarian cancer
    Sanchez Canovas, M.
    Lopez Robles, J.
    Garcia Verdejo, F. J.
    Cacho Lavin, D.
    Guirao, S.
    Garrido Fernandez, A.
    Coma Salvans, E.
    Quintanar Verduguez, T.
    Salvador Coloma, C.
    Fernandez Garay, D.
    Cumplido, J. D.
    Ferrer Perez, A. I.
    Carbo Bague, A.
    Teigell Munoz, F. J.
    Munoz Martin, A. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1095 - S1095
  • [7] Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer
    Kulkarni, Sanat
    Gajjar, Ketankumar
    Madhusudan, Srinivasan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [8] Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions
    Caruso, Giuseppe
    Tomao, Federica
    Parma, Gabriella
    Lapresa, Mariateresa
    Multinu, Francesco
    Palaia, Innocenza
    Aletti, Giovanni
    Colombo, Nicoletta
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (04) : 431 - 443
  • [9] Expression of poly(ADP-ribose) polymerase (PARP) in ovarian serous carcinoma
    Brustmann, H
    LABORATORY INVESTIGATION, 2006, 86 : 173A - 173A
  • [10] Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases
    Kasherman, Lawrence
    Madariaga, Ainhoa
    Rouzbahman, Marjan
    Murphy, Kieran
    Shultz, David
    Stockley, Tracy
    Oza, Amit M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 139 - 143
12345